Who are CoronaVac/BNT162b2's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): BNT162b2 Bivalent (WT/OMI BA.1), Tozinameran 6 months to 4 years of age, BNT162b7 Monovalent (OMI BA.4/BA.5), Famtozinameran 5 to 11 Years of age, Influenza, Tozinameran 12 Years of age and older.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/coronavac-bnt162b2.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

CoronaVac/BNT162b2 — Competitive Intelligence Brief

CoronaVac/BNT162b2 (CoronaVac/BNT162b2) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: vaccine. Area: Immunology / Infectious Disease.

phase 3 vaccine SARS-CoV-2 spike protein Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

CoronaVac/BNT162b2 (CoronaVac/BNT162b2) — Institut Pasteur de Tunis. This is a combination COVID-19 vaccine regimen using CoronaVac (inactivated virus vaccine) followed by BNT162b2 (mRNA vaccine) to stimulate immune responses against SARS-CoV-2.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CoronaVac/BNT162b2 TARGET	CoronaVac/BNT162b2	Institut Pasteur de Tunis	phase 3	vaccine	SARS-CoV-2 spike protein
BNT162b2 Bivalent (WT/OMI BA.1)	bnt162b2-bivalent-wt-omi-ba-1	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein
Tozinameran 6 months to 4 years of age	tozinameran-6-months-to-4-years-of-age	Pfizer	marketed	vaccine	SARS-CoV-2 spike protein
BNT162b7 Monovalent (OMI BA.4/BA.5)	bnt162b7-monovalent-omi-ba-4-ba-5	Pfizer	marketed	vaccine	SARS-CoV-2 spike protein
Famtozinameran 5 to 11 Years of age	famtozinameran-5-to-11-years-of-age	Pfizer	marketed	Monoclonal antibody	SARS-CoV-2 spike protein
Influenza	Influenza and COVID-19 Combination A	BioNTech	marketed	Non-Standardized Plant Allergenic Extract [EPC]	SARS-CoV-2 spike protein and influenza hemagglutinin protein
Tozinameran 12 Years of age and older	tozinameran-12-years-of-age-and-older	Pfizer	marketed	vaccine	SARS-CoV-2 spike protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (vaccine class)

Pfizer · 20 drugs in this class
Sanofi Pasteur, a Sanofi Company · 20 drugs in this class
GlaxoSmithKline · 12 drugs in this class
Merck Sharp & Dohme LLC · 12 drugs in this class
Centers for Disease Control and Prevention · 9 drugs in this class
Zhejiang Provincial Center for Disease Control and Prevention · 7 drugs in this class
Jiangsu Province Centers for Disease Control and Prevention · 6 drugs in this class
Beijing Center for Disease Control and Prevention · 6 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 5 drugs in this class
Sinovac Biotech Co., Ltd · 4 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CoronaVac/BNT162b2 — Competitive Intelligence Brief. https://druglandscape.com/ci/coronavac-bnt162b2. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab